Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders

Attention-deficit hyperactivity disorder; Pleiotropy; Substance use disorders

Detalles Bibliográficos
Autores: Koller, Dora, Mitjans, Marina, Kouakou, Manuela, Friligkou, Eleni, Cabrera-Mendoza, Brenda, Deak, Joseph, Soler Artigas, María, Llonga, Natalia, Ribases, Marta, Ramos-Quiroga, Josep Antoni
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/12211
Acceso en línea:https://hdl.handle.net/11351/12211
Access Level:acceso abierto
Palabra clave:Comorbiditat
Trastorn per dèficit d'atenció amb hiperactivitat - Aspectes genètics
Diagnòstic dual
Abús de substàncies
DISEASES::Chemically-Induced Disorders::Substance-Related Disorders
Other subheadings::Other subheadings::Other subheadings::/genetics
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with Hyperactivity
PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity
ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias
Otros calificadores::Otros calificadores::Otros calificadores::/genética
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos conductuales disruptivos y déficit de atención::trastornos de déficit de atención con hiperactividad
SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad
id ES_4358c8a2a5cbeb4eacf860b7c32b27b3
oai_identifier_str oai:scientiasalut.gencat.cat:11351/12211
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
title Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
spellingShingle Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
Koller, Dora
Comorbiditat
Trastorn per dèficit d'atenció amb hiperactivitat - Aspectes genètics
Diagnòstic dual
Abús de substàncies
DISEASES::Chemically-Induced Disorders::Substance-Related Disorders
Other subheadings::Other subheadings::Other subheadings::/genetics
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with Hyperactivity
PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity
ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias
Otros calificadores::Otros calificadores::Otros calificadores::/genética
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos conductuales disruptivos y déficit de atención::trastornos de déficit de atención con hiperactividad
SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad
title_short Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
title_full Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
title_fullStr Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
title_full_unstemmed Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
title_sort Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disorders
dc.creator.none.fl_str_mv Koller, Dora
Mitjans, Marina
Kouakou, Manuela
Friligkou, Eleni
Cabrera-Mendoza, Brenda
Deak, Joseph
Soler Artigas, María
Llonga, Natalia
Ribases, Marta
Ramos-Quiroga, Josep Antoni
author Koller, Dora
author_facet Koller, Dora
Mitjans, Marina
Kouakou, Manuela
Friligkou, Eleni
Cabrera-Mendoza, Brenda
Deak, Joseph
Soler Artigas, María
Llonga, Natalia
Ribases, Marta
Ramos-Quiroga, Josep Antoni
author_role author
author2 Mitjans, Marina
Kouakou, Manuela
Friligkou, Eleni
Cabrera-Mendoza, Brenda
Deak, Joseph
Soler Artigas, María
Llonga, Natalia
Ribases, Marta
Ramos-Quiroga, Josep Antoni
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Koller D] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA. Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. [Mitjans M] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain. Sant Joan de Déu Research Institute (IR-SJD), Esplugues de Llobregat, Spain. [Kouakou M] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. [Friligkou E, Cabrera-Mendoza B, Deak JD] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA. [Llonga N] Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Soler Artigas M, Ribasés M] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ramos-Quiroga JA] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Comorbiditat
Trastorn per dèficit d'atenció amb hiperactivitat - Aspectes genètics
Diagnòstic dual
Abús de substàncies
DISEASES::Chemically-Induced Disorders::Substance-Related Disorders
Other subheadings::Other subheadings::Other subheadings::/genetics
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with Hyperactivity
PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity
ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias
Otros calificadores::Otros calificadores::Otros calificadores::/genética
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos conductuales disruptivos y déficit de atención::trastornos de déficit de atención con hiperactividad
SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad
topic Comorbiditat
Trastorn per dèficit d'atenció amb hiperactivitat - Aspectes genètics
Diagnòstic dual
Abús de substàncies
DISEASES::Chemically-Induced Disorders::Substance-Related Disorders
Other subheadings::Other subheadings::Other subheadings::/genetics
PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with Hyperactivity
PUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::Comorbidity
ENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustancias
Otros calificadores::Otros calificadores::Otros calificadores::/genética
PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos conductuales disruptivos y déficit de atención::trastornos de déficit de atención con hiperactividad
SALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidad
description Attention-deficit hyperactivity disorder; Pleiotropy; Substance use disorders
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/12211
url https://hdl.handle.net/11351/12211
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Psychiatry Research;333
https://doi.org/10.1016/j.psychres.2024.115758
info:eu-repo/grantAgreement/EC/H2020/667302
info:eu-repo/grantAgreement/EC/H2020/728018
info:eu-repo/grantAgreement/EC/H2020/841899
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407018024960000
spelling Genetic contribution to the comorbidity between attention-deficit/hyperactivity disorder and substance use disordersKoller, DoraMitjans, MarinaKouakou, ManuelaFriligkou, EleniCabrera-Mendoza, BrendaDeak, JosephSoler Artigas, MaríaLlonga, NataliaRibases, MartaRamos-Quiroga, Josep AntoniComorbiditatTrastorn per dèficit d'atenció amb hiperactivitat - Aspectes genèticsDiagnòstic dualAbús de substànciesDISEASES::Chemically-Induced Disorders::Substance-Related DisordersOther subheadings::Other subheadings::Other subheadings::/geneticsPSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Neurodevelopmental Disorders::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with HyperactivityPUBLIC HEALTH::Epidemiology and Biostatistics::Epidemiology::Health-Disease Process::ComorbidityENFERMEDADES::trastornos inducidos químicamente::trastornos relacionados con sustanciasOtros calificadores::Otros calificadores::Otros calificadores::/genéticaPSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del desarrollo neurológico::trastornos conductuales disruptivos y déficit de atención::trastornos de déficit de atención con hiperactividadSALUD PÚBLICA::epidemiología y bioestadística::epidemiología::proceso salud-enfermedad::comorbilidadAttention-deficit hyperactivity disorder; Pleiotropy; Substance use disordersTrastorn per dèficit d'atenció amb hiperactivitat; Pleiotropia; Trastorns per consum de substànciesTrastorno por déficit de atención con hiperactividad; Pleiotropía; Trastornos por consumo de sustanciasWe characterized the genetic architecture of the attention-deficit hyperactivity disorder-substance use disorder (ADHD-SUD) relationship by investigating genetic correlation, causality, pleiotropy, and common polygenic risk. Summary statistics from genome-wide association studies (GWAS) were used to investigate ADHD (Neff = 51,568), cannabis use disorder (CanUD, Neff = 161,053), opioid use disorder (OUD, Neff = 57,120), problematic alcohol use (PAU, Neff = 502,272), and problematic tobacco use (PTU, Neff = 97,836). ADHD, CanUD, and OUD GWAS meta-analyses included cohorts with case definitions based on different diagnostic criteria. PAU GWAS combined information related to alcohol use disorder, alcohol dependence, and the items related to alcohol problematic consequences assessed by the alcohol use disorders identification test. PTU GWAS was generated a multi-trait analysis including information regarding Fagerström Test for Nicotine Dependence and cigarettes per day. Linkage disequilibrium score regression analyses indicated positive genetic correlation with CanUD, OUD, PAU, and PTU. Genomic structural equation modeling showed that these genetic correlations were related to two latent factors: one including ADHD, CanUD, and PTU and the other with OUD and PAU. The evidence of a causal effect of PAU and PTU on ADHD was stronger than the reverse in the two-sample Mendelian randomization analysis. Conversely, similar strength of evidence was found between ADHD and CanUD. CADM2 rs62250713 was a pleiotropic SNP between ADHD and all SUDs. We found seven, one, and twenty-eight pleiotropic variants between ADHD and CanUD, PAU, and PTU, respectively. Finally, OUD, CanUD, and PAU PRS were associated with increased odds of ADHD. Our findings demonstrated the contribution of multiple pleiotropic mechanisms to the comorbidity between ADHD and SUDs.The authors acknowledge support from the Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission (101028810), the National Institutes of Health (R33 DA047527, R21 DC018098, RF1 MH132337, K99 AG078503, T32 MH014276, T32 AA02825, K01 DA051759), Veterans Affairs Office of Research & Development (5IK2BX005058 and CX001849-01), Alzheimer's Association Research Fellowship (AARF-22-967171), American Foundation for Suicide Prevention (PDF-1-022-21), the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR, 2021-SGR-01093), grants RYC-2017-21636 and RYC2021-033573-I funded by MCIN/AEI/10.13039/501100011033 and by the European Union “NextGenerationEU”/PRTR” Ramón y Cajal contract (RYC-2017-21636) and One Mind. BC received financial support from the Spanish ‘Ministerio de Ciencia, Innovación y Universidades’ (PID2021-1277760B-I100), ‘Generalitat de Catalunya/AGAUR’ (2021-SGR-01093), ICREA Academia 2021, ‘Fundació La Marató de TV3’ (202218-31), and the European Union H2020 Program [H2020/2014-2020] under grant agreements n° 667302 (CoCA), 728018 (Eat2beNICE), and 841899 (GRASAD). We thank the participants and the investigators involved in the UK Biobank, Million Veteran Program, and the Psychiatric Genomics Consortium for making their data publicly available. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.ElsevierInstitut Català de la Salut[Koller D] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA. Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. [Mitjans M] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Catalonia, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain. Sant Joan de Déu Research Institute (IR-SJD), Esplugues de Llobregat, Spain. [Kouakou M] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. [Friligkou E, Cabrera-Mendoza B, Deak JD] Department of Psychiatry, Yale School of Medicine, New Haven, CA, USA. Veterans Affairs Connecticut Healthcare Center, West Haven, CA, USA. [Llonga N] Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Soler Artigas M, Ribasés M] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Psiquiatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ramos-Quiroga JA] Department of Genetics, Microbiology, and Statistics, Faculty of Biology, University of Barcelona, Barcelona, Spain. Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain. Grup de Recerca de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Psiquiatria i Medicina Forense, Universitat Autònoma de Barcelona, Bellaterra, SpainVall d'Hebron Barcelona Hospital Campus202420242024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/12211Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésPsychiatry Research;333https://doi.org/10.1016/j.psychres.2024.115758info:eu-repo/grantAgreement/EC/H2020/667302info:eu-repo/grantAgreement/EC/H2020/728018info:eu-repo/grantAgreement/EC/H2020/841899Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/122112026-06-12T09:38:37Z
score 15,812429

Similares en LA Referencia